Keywords: Shre, Lialda, Ulcerative colitis, USA, FDA
Shire’s Lialda now OKed for ulcerative colitis maintenance of remission in the USA
Article | 19 July 2011
The US Food and Drug Administration has approved Ireland-headquartered specialty drugmaker Shire’s (LSE: SHP) Lialda (mesalamine) delayed-release tablets ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
